Behind KANJINTI®

THE AMGEN Experience you can trust

#1 Prescribed Trastuzumar Biosimilar
Behind KANJINTI®
THE AMGEN EXPERIENCE YOU CAN TRUST
Kanjinti®
The first and only Herceptin® Biosimilar with SINGLE-TRANSITION study data in the early breast cancer (eBC) setting1-8

KANJINTI® is indicated for the treatment of:1

  • HER2-overexpressing breast cancer
  • HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
trastuzumab-anns (KANJINTI®)
is a recommended treatment option
IN THE NCCN GUIDELINES®9,*
ribbon
KANJINTI®

The first and only Herceptin® biosimilar with SINGLE-TRANSITION study data in the early breast cancer (eBC) seTting1-8

trastuzumab-anns
(KANJINTI®)
is a recommended treatment option
IN THE NCCN GUIDELINES®9,*
KANJINTI® sets a rigorous standard
for Herceptin® biosimilarity
The first and only Herceptin® biosimilar with singletransition study data in the eBC setting

The first and only

Herceptin® biosimilar with single-transition study data in the

eBCSETTING1-8

btn-medi_rainbow-svgtotality of evidence

Identical Dosing

to Herceptin® IV

Available in a
Multi-dose‡ 420 mg vial1

btn-medi_rainbow-svgdosing
Comprehensive support for you and your patients

The same support you’ve come to expect from AMGEN

Established Q-code: Q5117

btn-medi_rainbow-svgsupport

Backed by
Amgen Expertise

40+

Years

experience in biologics

btn-medi_rainbow-svgbiosimilar expertise
AMGEN® Biosimilars

Get the story behind Amgen's
commitment to biosimilars.

Amgen Biosimilars

*NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recognize FDA-approved trastuzumab biosimilars for use in place of trastuzumab (Herceptin®). NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

†Current as of April 2021.

‡Multi-dose when reconstituted with Bacteriostatic Water for Injection.